- 2025.1.08 (Report) Representative Nakamura Delivers a Lecture at the Chemistry Committee Joint Meeting of the Science Council of Japan
- 2024.12.30Patent owned by Veritas In Silico to Become Effective in Europe
- 2024.12.23Liverpool ChiroChem and VIS to Enter into a Collaboration Development & Commercialization Agreement for mRNA-targeted Small Molecule Drugs
- 2024.12.13Company Presentation
- 2024.12.13Revised Financial Forecast for FY2024
- 2024.11.29(Report) Veritas In Silico participate in the 41st Medicinal Chemistry Symposium
- 2024.11.13Non-consolidated Financial Results for the Nine Months Ended September 30, 2024 [Under Japanese GAAP]
- 2024.11.13Fiscal Year Ending December 2024, 3rd Quarter, Financial Results
- 2024.11.13Organizational Reforms and Personnel Changes of General Managers
- 2024.11.12(Report) CSO’s talk in the Company Presentations session at BIO-Europe 2024
- 2024.06.19Veritas In Silico Announces Milestone Achievement in Collaborative Research with Takeda
- 2024.02.08Veritas In Silico Listed on the Growth Market of the Tokyo Stock Exchange
- 2023.12.21RaQualia Pharma and Veritas In Silico announce that both companies have achieved the milestone in a joint research collaboration for mRNA-targeted small molecule drug discovery
- 2023.12.08Mitsubishi Gas Chemical and Veritas In Silico start to discuss the research collaboration of RNA targeting drug discovery program
- 2023.06.23Veritas In Silico and Takeda Enter Into Collaborative Research and License Agreement for mRNA-Targeted Small Molecule Drugs
- 2023.05.22Oncodesign Services and Veritas In Silico enter into business cooperation on developing mRNA-targeted small molecule drugs
- 2022.12.27RaQualia Pharma and Veritas in Silico enter into a new joint research agreement for mRNA-targeted small molecule drug discovery
- 2022.10.04Veritas In Silico Begins RNase-Recruiting Small Molecule Screening for RIBOTAC Design and Synthesis
- 2021.12.27Veritas In Silico Announces 1.4 Billion JPY (Approx. $12.2 Million) Series C Financing
- 2021.11.25Veritas in Silico Signs Joint Drug Discovery Research Agreement with Shionogi
- 2025.01.08(Report) Representative Nakamura Delivers a Lecture at the Chemistry Committee Joint Meeting of the Science Council of Japan
- 2024.11.29(Report) Veritas In Silico participate in the 41st Medicinal Chemistry Symposium
- 2024.11.12(Report) CSO’s talk in the Company Presentations session at BIO-Europe 2024
- 2024.10.24Veritas In Silico Inc. to Announce Third Quarter Fiscal Year 2024 Financial Results on November 13
- 2024.10.18(Scheduled for Nov. 4) CSO to present in the Company Presentations session at BIO Europe 2024
- 2024.10.17(Report) “Japan Healthcare Venture Summit 2024” hosted by the Ministry of Health, Labour and Welfare
- 2024.10.16Veritas In Silico to participate in the 41st Medicinal Chemistry Symposium for invited lecture, poster discussion, and company exhibition
- 2024.10.04(Scheduled for Oct. 29) Senior Investigator to Present at CBI Annual Meeting 2024
- 2024.09.05(Report) Representative Nakamura present at “JASIS Collaboration – Public Utilization Platform Brings Innovation to Research” hosted by MEXT
- 2024.08.21CEO Nakamura to present at “JASIS Collaboration; Public utilization platform brings innovation to research ~Measurement and analysis systems open up new research horizons~” hosted by MEXT on Sep. 4
- 2024.12.30Patent owned by Veritas In Silico to Become Effective in Europe
- 2024.12.23Liverpool ChiroChem and VIS to Enter into a Collaboration Development & Commercialization Agreement for mRNA-targeted Small Molecule Drugs
- 2024.12.13Company Presentation
- 2024.12.13Revised Financial Forecast for FY2024
- 2024.11.13Non-consolidated Financial Results for the Nine Months Ended September 30, 2024 [Under Japanese GAAP]
- 2024.11.13Fiscal Year Ending December 2024, 3rd Quarter, Financial Results
- 2024.11.13Organizational Reforms and Personnel Changes of General Managers
- 2024.10.09Mitsubishi Gas Chemical and Veritas In Silico, Sign MOU on Joint Business of Research and Development of RNA-Targeted Drugs
- 2024.10.09Liverpool ChiroChem and Veritas In Silico Agree to Form a Strategic Partnership of mRNA-Targeted Drug Discovery and Development
- 2024.09.24Notification regarding Achievement of Milestone in Joint Drug Discovery Research with Shionogi & Co., Ltd.